<qa>  What is the purpose of this extension protocol?The objective of this extension protocol is to collect safety data serious and non-serious adverse events and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 until a decision regarding reimbursement in France is effective for canakinumab Ilaris in these indications. 